+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Middle East and Africa Hyperphosphatemia Drugs Market 2019-2027

  • ID: 4791829
  • Report
  • Region: Africa, Middle East
  • 58 pages
  • Triton Market Research
1 of 3

FEATURED COMPANIES

  • Amag Pharmaceuticals
  • Bruno Farmaceutici S.P.A.
  • Fermenta Biotech, Ltd.
  • Johnson and Johnson
  • Royal Dsm N.V.
  • Shire
  • MORE
Market Outlook

The Middle East and African hyperphosphatemia drugs market is anticipated to upsurge with a CAGR of 18.96% in the forecasting years of 2019-2027.

Turkey, the UAE, Saudi Arabia, South Africa and countries in rest of the Middle East & Africa together form the hyperphosphatemia drugs market in the MEA region.

The growth of the Africa hyperphosphatemia drugs market is primarily driven by the rising awareness of the condition among the government and the public in the region. The global health standards being set by the World Health Organization (WHO) also forces the African government to implement safe and secure delivery procedures in hospitals with impetus given to complete healthcare. Hence, the African government is increasingly spending huge amounts of money on improving healthcare facilities in the region. In addition to this, the rising literacy rate in Africa is further enabling people to pursue clean and healthy daily living practices. Additional care is being given to pregnant women to successfully deliver a healthy child while maintaining the mother’s health. This would further enable the people in the region to have access to the hyperphosphatemia treatment procedures and thereby, grow the demand for hyperphosphatemia drugs.

Competitive Outlook

The dominant companies in the market include Bio-Tech Pharmacal, Fermenta Biotech, Ltd., Ultragenyx Pharmaceutical, Inc., Shire, Bruno Farmaceutici S.p.A., Royal DSM N.V., Roche Diagnostics Corporation, Johnson and Johnson, AMAG Pharmaceuticals, Cipla, Keryx Biopharmaceuticals, Inc., Pfizer, Inc., Sun Pharmaceutical Industries, Ltd., Fresenius Medical Care, Zeria Pharmaceutical and Sanofi.

Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Amag Pharmaceuticals
  • Bruno Farmaceutici S.P.A.
  • Fermenta Biotech, Ltd.
  • Johnson and Johnson
  • Royal Dsm N.V.
  • Shire
  • MORE
1. Middle East and Africa Hyperphosphatemia Drugs Market - Summary

2. Industry Outlook
2.1. Market Definition
2.2. Porter’s Five Force Model
2.2.1. Threat of New Entrants
2.2.2. Bargaining Power of Buyers
2.2.3. Bargaining Power of Suppliers
2.2.4. Threat of Substitute Product
2.2.5. Intensity of Competitive Rivalry
2.3. Vendor Scorecard
2.4. Key Buying Outlook
2.5. Key Insights
2.6. Key Market Trends
2.7. Guidelines Related to the Phosphate Binders
2.8. Market Drivers
2.8.1. Chronic Disorders are Increasing Rapidly
2.8.2. Increase in Public Cognizance
2.8.3. Increase in Geriatric Population
2.9. Market Restraints
2.9.1. Side-Effects Related to the Usage of Hyperphosphatemia Drugs
2.9.2. Strict Food and Drug Administration (Fda) Regulations
2.10. Market Opportunities
2.10.1. Rise in the Aging Population
2.11. Market Challenges
2.11.1. Alternative Dialysis Techniques
2.11.2. Accessibility of Drugs is Limited
2.11.3. Non-Adherence to Treatment Regimes

3. Hyperphosphatemia Drugs Market Outlook - By Dosages
3.1. Solid
3.1.1. Tablet
3.1.2. Powder
3.2. Liquid
3.2.1. Solution

4. Hyperphosphatemia Drugs Market Outlook - By Formulation
4.1.1. Calcium-Based Phosphate Binders
4.1.2. Aluminum-Based Phosphate Binders
4.1.3. Magnesium-Based Phosphate Binders
4.1.4. Iron-Based Phosphate Binders
4.1.5. Other Phosphate Binders

5. Hyperphosphatemia Drugs Market - Regional Outlook
5.1. Middle East and Africa
5.1.1. Country Analysis
5.1.1.1. Saudi Arabia
5.1.1.2. Turkey
5.1.1.3. United Arab Emirates
5.1.1.4. South Africa
5.1.1.5. Rest of Middle East & Africa

6. Competitive Landscape
6.1. Johnson and Johnson
6.2. Zeria Pharmaceutical
6.3. Amag Pharmaceuticals
6.4. Sanofi
6.5. Bruno Farmaceutici S.P.A.
6.6. Roche Diagnostics Corporation
6.7. Royal Dsm N.V.
6.8. Shire
6.9. Cipla
6.10. Ultragenyx Pharmaceutical, Inc.
6.11. Fermenta Biotech, Ltd.
6.12. Biotech Pharmacal
6.13. Sun Pharmaceutical Industries, Ltd.
6.14. Keryx Biopharmaceuticals, Inc.
6.15. Fresenius Medical Care
6.16. Pfizer, Inc.

7. Methodology & Scope
7.1. Research Scope
7.2. Sources of Data
7.3. Research Methodology

Table List
Table 1 Middle East and Africa Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Table 2 Phosphorus Levels in Select Foods
Table 3 Middle East and Africa Hyperphosphatemia Drugs Market By Formulation 2019-2027 ($ Million)
Table 4 Diagnosis and Clinical Indicators of Chronic Kidney Disease
Table 5 Middle East and Africa Hyperphosphatemia Drugs Market Country Analysis 2019-2027 ($ Million)

Figure List
Figure 1 Porter’s Five Forces Model of Hyperphosphatemia Drugs Market
Figure 2 Iron-Based Hyperphosphatemia Drug Approval Status 2014-2017
Figure 3 Rate of Adherence to Phosphate Binders
Figure 4 Middle East and Africa Hyperphosphatemia Drugs Market in Calcium-Based Phosphate Binders 2019-2027 ($ Million)
Figure 5 Middle East and Africa Hyperphosphatemia Drugs Market in Aluminum-Based Phosphate Binders 2019-2027 ($ Million)
Figure 6 Middle East and Africa Hyperphosphatemia Drugs Market in Magnesium-Based Phosphate Binders 2019-2027 ($ Million)
Figure 7 Middle East and Africa Hyperphosphatemia Drugs Market in Iron-Based Phosphate Binders 2019-2027 ($ Million)
Figure 8 Middle East and Africa Hyperphosphatemia Drugs Market in Other Phosphate Binders 2019-2027 ($ Million)
Figure 9 Middle East and Africa Hyperphosphatemia Drugs Market Share 2018 & 2027 (%)
Figure 10 Middle East and Africa Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 11 Saudi Arabia Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 12 Turkey Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 13 United Arab Emirates Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 14 South Africa Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Figure 15 Rest of Middle East & Africa Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Johnson and Johnson
  • Zeria Pharmaceutical
  • Amag Pharmaceuticals
  • Sanofi
  • Bruno Farmaceutici S.P.A.
  • Roche Diagnostics Corporation
  • Royal Dsm N.V.
  • Shire
  • Cipla
  • Ultragenyx Pharmaceutical, Inc.
  • Fermenta Biotech, Ltd.
  • Biotech Pharmacal
  • Sun Pharmaceutical Industries, Ltd.
  • Keryx Biopharmaceuticals, Inc.
  • Fresenius Medical Care
  • Pfizer, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll